1. IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis. (April 2022) Authors: Huang, C.N.; Tsou, S.H.; Li, H.H.; Lin, S.C.; Lin, C.L. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IDF21-0180 Alpelisib-induced coexisting of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State in Metastatic Breast Cancer. (April 2022) Authors: Li, L.C.; Hsu, C.M.; Yang, Y.S.; Lo, S.C.; Huang, C.N.; Kornelius, E. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. IDF21-0194 Impact of COVID-19 during period of Level 3 alert on access to diabetes care in central Taiwan. (April 2022) Authors: Yang, Y.S.; Huang, C.N.; Kornelius, E.; Shih-chang, L. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗